Compounds > ageliferin
Page last updated: 2024-11-12

ageliferin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ageliferin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11169518
CHEMBL ID1187442
MeSH IDM0502854

Synonyms (6)

Synonym
ageliferin
CHEMBL1187442
117417-64-8
DTXSID40457473
Q4691976
n-[[(5s,6r,7r)-2-amino-7-(2-amino-1h-imidazol-5-yl)-6-[[(4-bromo-1h-pyrrole-2-carbonyl)amino]methyl]-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methyl]-4-bromo-1h-pyrrole-2-carboxamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1867337Hemolytic activity against BALB/c mouse erythrocyte at 100 uM measured after 2 hrs relative to control
AID1867333Antibacterial activity against Enterococcus faecalis ATCC 29212 incubated for 24 hrs by broth microdilution method
AID1867328Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae id-146/19 incubated for 24 hrs by broth microdilution method
AID1867326Antibacterial activity against ESBL-producing Escherichia coli ATCC 35218 incubated for 24 hrs by broth microdilution method
AID1867336Antibacterial activity against oxacillin-resistant Staphylococcus aureus ATCC 33591 incubated for 24 hrs by broth microdilution method
AID1867325Antibacterial activity against Escherichia coli ATCC 25922 incubated for 24 hrs by broth microdilution method
AID1867332Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa S-6065/06 incubated for 24 hrs by broth microdilution method
AID1867324Cytotoxicity against human L5178Y cells assessed as inhibition of cell viability at 50 uM incubated for 72 hrs by MTT assay relative to control
AID1867331Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by broth microdilution method
AID1867329Antibacterial activity against Acinetobacter baumannii ATCC 19606 incubated for 24 hrs by broth microdilution method
AID1867335Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 24 hrs by broth microdilution method
AID1867327Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated for 24 hrs by broth microdilution method
AID1867334Antibacterial activity against vancomycin resistant Enterococcus faecalis ATCC 51299 incubated for 24 hrs by broth microdilution method
AID1867323Cytotoxicity against human OVCAR-3 cells
AID1867330Antibacterial activity against carbapenem-resistant Acinetobacter baumannii id-261/16 incubated for 24 hrs by broth microdilution method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (54.55)29.6817
2010's3 (27.27)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.31 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.76100pyrrole;
secondary amine
2-aminobenzimidazole
2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd. 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group.		2.110benzimidazolesmarine xenobiotic metabolite
manganese
Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.		2.0610elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
quadricyclane
quadricyclane: structure in first source		7.0210
2-aminoimidazole
2-aminoimidazole: from catabolism of arginine		2.110
sceptrin
sceptrin: structure given in first source; isolated from marine sponges of the genus Agelas; RN from CHEMLINE		2.9440pyrroles;
secondary carboxamide
oroidin
oroidin: from marine sponges of the genus Agelas; structure in first source		2.4720pyrroles;
secondary carboxamide		metabolite
palau'amine
palau'amine: structure in first source		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials